Osimertinib Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 40 mg, 80 mg
Reference Brands: Tagrisso® (US & EU)
Category:
Oncology Cancer Care
Osimertinib Tablets (brand name Tagrisso®) are used to treat EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. As a third-generation tyrosine kinase inhibitor (TKI), Osimertinib selectively targets EGFR mutations. Available in 40 mg and 80 mg strengths, it is a reliable solution for oncology treatment in US and EU markets, manufactured under GMP standards.
Osimertinib Tablets is available in Oral Tablets
and strengths such as 40 mg, 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Osimertinib Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Osimertinib Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Osimertinib Tablets are a third-generation tyrosine kinase inhibitor (TKI) used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. Marketed under the brand name Tagrisso®, Osimertinib selectively targets and inhibits EGFR mutations, providing a more precise treatment for metastatic NSCLC. Available in 40 mg and 80 mg tablet strengths, Osimertinib offers significant benefits in advanced lung cancer care. Manufactured under GMP-compliant conditions, it is an effective and reliable solution for US and EU pharmaceutical distributors looking to provide cutting-edge oncology treatments in precision medicine.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing